A compound series with a favorable safety profile for which a patent application was recently submitted, has anti-inflammatory and bronchodilatory properties equivalent to those of RESP1000 and RESP2000, but is completely outside these compound series with respect to patents.

The project is in a preclinical phase and is the company’s prioritized project for development of new medications for treatment of COPD and severe asthma.

A compound series of drug candidates with bronchodilatory and anti-inflammatory properties under development to enable treatment of both COPD and asthma.

The project is in preclinical phase and in 2014 a license and collaboration agreement was signed with Cadila Pharmaceuticals Ltd. for preclinical and clinical development of selected drug candidates from the RESP1000 series.

A series of new chemical substances, completely different from RESP1000, that have bronchodilatory properties and the potential to be developed into drugs for treatment of COPD and severe asthma.

The RESP2000 compound series contains substances that affect the mitochondria (in simple terms, the cellular energy sources). In addition, certain exploratory studies will be conducted for other indications. This project is currently in early preclinical phase.

A project aimed at diagnosing conditions such as cardiovascular diseases using PET imaging. The patent-protected RESP3000 compound series represents a further development of the RESP2000 compound series.

Respiratorius has completed a study of RES3105, the selected candidate from the compound series, with promising results.